A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS

The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.

Inclusion Criteria:

• Healthy individuals as determined by medical evaluation
• Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion Criteria:

• Clinically significant medical conditions
• History of HIV infection, hepatitis B, or hepatitis C
• BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
• Clinically relevant ECG abnormalities
• Previous study drug administration within 30 days or 5 half-lives of first planned dose
• History of drug/alcohol abuse or >20 cigarettes/day